TheraLase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) has been boosted by a second patent for its lead anti-cancer compound TLD-1433.
It comes from the US Patent and Trademark Office (USPTO) and is entitled: "Metal-Based Thiophene Photodynamic Compounds and Their Use," which was issued on June 13 and is a continuation of the previous patent.
Light activated photo dynamic compounds
In simple terms, Theralase is developing light activated photo dynamic compounds (PDCs) to destroy cancer, where the compound is absorbed by the tumour and activated by light.
This patent deals with the composition of certain PDCs used as therapeutic agents and as in vivo diagnostic agents for treating or preventing diseases.
Building patent portfoio..
Roger Dumoulin-White, president and chief executive of Theralase, said: "Theralase continues to build its patent portfolio for its anti-cancer division, providing protection from competition as the company advances towards commercialization of this technology through the clinical study process.
"The company is actively involved in the second phase of a phase Ib clinical trial for non-muscle invasive bladder cancer (NMIBC) focused on enrolling and treating the next six patients at the therapeutic dose of its lead PDC, TLD-1433 (0.70 milligram/square centimetre)."
Shares are unchanged at $0.375.